Beta-cell Function in Glucose Abnormalities and Acute Myocardial Infarction
Status:
Completed
Trial end date:
2010-11-01
Target enrollment:
Participant gender:
Summary
A three months, double-blind, randomised, parallel-group study evaluating the efficacy of
sitagliptin (Januvia™) versus placebo on beta-cell function in patients with newly detected
glucose abnormalities and acute myocardial infarction or unstable angina pectoris.
Primary endpoint Improvement in beta-cell function measured by means of the insulinogenic
index (ΔI30/ΔG30) obtained from an oral glucose tolerance test (OGTT).
Secondary endpoints
1. Improvement of glucose tolerance by means of an OGTT
2. Improvement in endothelial function
3. Improvement in incretin-independent beta-cell function measured as the Acute Insulin
Response (ΔAIRG) during an intravenous glucose tolerance test